- Home
- UFCS vs MLYS Comparison
UFCS vs MLYS Comparison
Compare UFCS & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | MLYS |
|---|---|---|
| Founded | 1946 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 933.8M | 3.1B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | UFCS | MLYS |
|---|---|---|
| Price | $36.85 | $37.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $33.00 | ★ $47.33 |
| AVG Volume (30 Days) | 143.7K | ★ 1.6M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | ★ 118.04 | N/A |
| EPS | ★ 4.24 | N/A |
| Revenue | ★ $1,353,781,000.00 | N/A |
| Revenue This Year | $10.11 | N/A |
| Revenue Next Year | $3.33 | N/A |
| P/E Ratio | $8.71 | ★ N/A |
| Revenue Growth | ★ 12.12 | N/A |
| 52 Week Low | $24.11 | $8.24 |
| 52 Week High | $37.84 | $47.65 |
Technical Indicators
Market Signals| Indicator | UFCS | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 59.04 | 43.48 |
| Support Level | $36.16 | $36.01 |
| Resistance Level | $37.50 | $39.15 |
| Average True Range (ATR) | 0.91 | 1.81 |
| MACD | -0.02 | -0.16 |
| Stochastic Oscillator | 84.89 | 31.53 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.